ResearcherHeidelberg UniversityActive in the last 2 years

Dirk Theile

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4720-9242; OpenAlex author ID A5020225544. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 14

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic res… Last author DOI 10.3892/or.2025.9027 ↗
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Co-author DOI 10.1038/s43018-023-00628-6 ↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

John P. Neoptolemos · 2 shared papers, 2023–2026 · strength 0.43
- Paper Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but … DOI 10.3892/or.2025.9027 ↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗
Helma Röttgen · 1 shared paper, 2026 · strength 0.30
- Paper Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but … DOI 10.3892/or.2025.9027 ↗
Nicolas Hohmann · 1 shared paper, 2023 · strength 0.13
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗
Peter J. Bailey · 1 shared paper, 2023 · strength 0.13
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗
Shigenori Ei · 1 shared paper, 2023 · strength 0.13
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗
Jingyu An · 1 shared paper, 2023 · strength 0.13
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗
Markus Wolfgang Büchler · 1 shared paper, 2023 · strength 0.13
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗
Franco Fortunato · 1 shared paper, 2023 · strength 0.13
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗
Thilo Hackert · 1 shared paper, 2023 · strength 0.13
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗
Simon T. Barry · 1 shared paper, 2023 · strength 0.13
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗
Christoph Springfeld · 1 shared paper, 2023 · strength 0.13
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗
Xu Zhou · 1 shared paper, 2023 · strength 0.13
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗
Oliver Strobel · 1 shared paper, 2023 · strength 0.13
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗
Ulrike Heger · 1 shared paper, 2023 · strength 0.13
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.